NEW YORK -- Dr. Michael Sessler joined E-QURE Corp Board of Directors. Dr. Sessler is an important addition to E-QURE team, having in depth knowledge and experience in global business development coupled with medical understanding of the E-QURE BST and its clinical use.
Sessler began his career as a medical doctor. Beginning his studies with Medical and Clinical courses at Tel-Aviv University in Israel, he went on to study at Rome University where he received his Medicine School Graduate (MD). Also at Rome University, he studied Clinical Project Management, under the guidance of Prof. Rita Levi Montalccini, winner of The Nobel Prize in Physiology in 1986.
Since 1992, Dr. Sessler has held senior managerial positions at the Electra consumer Products part of Elco Group, with over 6,800 employees and sales turnover of $1.12 Bil, Elco is one of Israel's leading corporations. The Group combines private and public companies that deal with infrastructure industries related to the manufacturing of consumer products, sales, marketing, wholesaling and real estate. Beginning in 2000, Dr. Sessler was elevated to Senior Vice President.
Dr. Sessler served as Chairman of the Board of four companies and as director in six, in Spain and Italy. He has taken senior management courses at the Harvard Business School and the Israeli Management Institute as well as at General Electric and the Export Institute
About E-QURE
E-QURE Corp is a OTC QB listed company, developing, manufacturing and marketing the E-QURE BST (Bioelectrical Signal Therapy) that treats and cure chronic wounds such as; pressure ulcers; diabetics foot ulcers; venous stasis ulcers and; hard to heal ulcers. The E-QURE BST device had received few regulatory approvals in different part of the world that is currently being renewed. The company is seeking FDA approval for the device to start marketing in the US.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements, when we discuss the potential of E-QURE BST device to treat wounds. These forward-looking statements and their implications are based on the current expectations of the management of E-QURE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QURE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, E-QURE undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QURE, reference is made to E-QURE reports filed from time to time with the Securities and Exchange Commission.
Media Contact
E-QURE Corp
